These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 7599855)
1. Sepsis trials. Intersection of investigation, regulation, funding, and practice. Bernard GR Am J Respir Crit Care Med; 1995 Jul; 152(1):4-10. PubMed ID: 7599855 [No Abstract] [Full Text] [Related]
2. New immunotherapies for sepsis. Young LS; Wenzel RP Proc Assoc Am Physicians; 1995 Oct; 107(3):361-4. PubMed ID: 8608423 [No Abstract] [Full Text] [Related]
4. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866 [No Abstract] [Full Text] [Related]
5. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Marshall JC Nat Rev Drug Discov; 2003 May; 2(5):391-405. PubMed ID: 12750742 [TBL] [Abstract][Full Text] [Related]
6. [Anakinra for therapy of rheumatoid arthritis]. Tomoo T; Sumida T Nihon Rinsho; 2005 Jan; 63 Suppl 1():534-7. PubMed ID: 15799413 [No Abstract] [Full Text] [Related]
7. Emerging therapies in juvenile rheumatoid/idiopathic arthritis. Passo M Curr Probl Pediatr Adolesc Health Care; 2006 Mar; 36(3):97-103. PubMed ID: 16473286 [No Abstract] [Full Text] [Related]
8. Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome. Seitz M; Kamgang RK; Simon HU; Villiger PM Ann Rheum Dis; 2005 Dec; 64(12):1802-3. PubMed ID: 16284353 [No Abstract] [Full Text] [Related]
9. Novel therapies for treatment of rheumatoid arthritis. Piascik P J Am Pharm Assoc (Wash); 1997; NS37(1):14-6. PubMed ID: 9040165 [No Abstract] [Full Text] [Related]
10. Clinical sepsis trials. Abraham E Chest; 1994 Mar; 105(3 Suppl):53S-55S. PubMed ID: 8131613 [No Abstract] [Full Text] [Related]
11. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis]. Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722 [TBL] [Abstract][Full Text] [Related]
12. Why immunomodulatory therapies have not worked in sepsis. Abraham E Intensive Care Med; 1999 Jun; 25(6):556-66. PubMed ID: 10416906 [No Abstract] [Full Text] [Related]
13. Potential strategies for inflammatory mediator manipulation: retrospect and prospect. Fisher CJ; Zheng Y World J Surg; 1996 May; 20(4):447-53. PubMed ID: 8662133 [TBL] [Abstract][Full Text] [Related]
14. Endotoxin, sepsis, and the primrose path. O'Reilly M; Newcomb DE; Remick D Shock; 1999 Dec; 12(6):411-20. PubMed ID: 10588508 [No Abstract] [Full Text] [Related]
18. [Interleukin-1 inhibitors: a new alternative for the treatment of rheumatoid polyarthritis]. Gabay C Rev Med Suisse Romande; 2000 Jun; 120(6):529-33. PubMed ID: 11014098 [No Abstract] [Full Text] [Related]
19. New therapeutic approaches in sepsis: a critical review. Eidelman LA; Pizov R; Sprung CL Intensive Care Med; 1995 Nov; 21 Suppl 2():S269-72. PubMed ID: 8636535 [No Abstract] [Full Text] [Related]
20. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Dayer JM Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii3-10. PubMed ID: 12817089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]